Peggy Phillips - Dynavax Technologies Independent Director

DVAX Stock  USD 11.80  0.46  4.06%   

Director

Ms. Peggy V. Phillips serves as Independent Director of Dynavax Technologies Corporationrationration. Ms. Phillips was a member of our Board since August 2006. Ms. Phillips served on the board of directors of several biopharmaceutical companies PhaseRx, Inc. from 2016 to 2018, Tekmira Pharmaceuticals from 2014 to 2015, Portola Pharmaceuticals from 2006 to 2013, as well as the Naval Academy Foundation from 2003 to 2011. From 1996 until 2002, she served on the board of directors of Immunex Corporationrationration, a biotechnology company, and, from 1999, she served as its Chief Operating Officer until the company was acquired by Amgen in 2002. During her career at Immunex, she held positions of increasing responsibility in research, development, manufacturing, sales and marketing. As Senior Vice President for Pharmaceutical Development and General Manager for Enbrel from 1994 until 1998, she was responsible for clinical development and regulatory affairs as well as the launch, sales and marketing of the product. Prior to joining Immunex, Ms. Phillips worked at Miles Laboratories. The Board believes that Ms. Phillips provides significant experience in development and commercialization of biotechnology products. Her background and experience with larger, complex organizations provides significant operational and strategic insights in assessing the strategy of the Company and qualifies her to serve as a director since 2006.
Age 64
Tenure 18 years
Address 2100 Powell Street, EmeryVille, CA, United States, 94608
Phone510 848 5100
Webhttps://www.dynavax.com
Phillips holds a B.S. and a M.S. in microbiology from the University of Idaho.

Dynavax Technologies Management Efficiency

The company has return on total asset (ROA) of (0.0192) % which means that it has lost $0.0192 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.0106) %, meaning that it created substantial loss on money invested by shareholders. Dynavax Technologies' management efficiency ratios could be used to measure how well Dynavax Technologies manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.0067 in 2024. Return On Capital Employed is likely to drop to -0.04 in 2024. At this time, Dynavax Technologies' Total Assets are fairly stable compared to the past year. Other Current Assets is likely to rise to about 19.9 M in 2024, whereas Other Assets are likely to drop slightly above 3 M in 2024.
The company currently holds 256.91 M in liabilities with Debt to Equity (D/E) ratio of 0.61, which is about average as compared to similar companies. Dynavax Technologies has a current ratio of 2.71, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Dynavax Technologies until it has trouble settling it off, either with new capital or with free cash flow. So, Dynavax Technologies' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Dynavax Technologies sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Dynavax to invest in growth at high rates of return. When we think about Dynavax Technologies' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Gino SantiniCollegium Pharmaceutical
61
Julie McHughLantheus Holdings
53
John FreundCollegium Pharmaceutical
64
Rory RiggsIntracellular Th
65
Nancy LurkerAquestive Therapeutics
60
Tracy MarshbanksANI Pharmaceuticals
52
Dennis WalshDeciphera Pharmaceuticals LLC
50
Wendy DixonAlkermes Plc
62
Richard EdlinEagle Pharmaceuticals
57
Robert BreyerAlkermes Plc
73
James ScibettaAquestive Therapeutics
52
Sander FlaumEagle Pharmaceuticals
81
John CochranAquestive Therapeutics
52
Marla KesslerIronwood Pharmaceuticals
48
John LongeneckerPacira Pharmaceuticals
70
Paul HastingsPacira Pharmaceuticals
58
Patrick HeronCollegium Pharmaceutical
44
Gail FarfelDurect
53
Stephen ShohetAmphastar P
82
Sriram VenkataramanLantheus Holdings
44
Julie McHughIronwood Pharmaceuticals
60
Dynavax Technologies Corporation, a biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. Dynavax Technologies Corporation was incorporated in 1996 and is headquartered in Emeryville, California. Dynavax Technologies operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 311 people. Dynavax Technologies (DVAX) is traded on NASDAQ Exchange in USA. It is located in 2100 Powell Street, EmeryVille, CA, United States, 94608 and employs 408 people. Dynavax Technologies is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Dynavax Technologies Leadership Team

Elected by the shareholders, the Dynavax Technologies' board of directors comprises two types of representatives: Dynavax Technologies inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Dynavax. The board's role is to monitor Dynavax Technologies' management team and ensure that shareholders' interests are well served. Dynavax Technologies' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Dynavax Technologies' outside directors are responsible for providing unbiased perspectives on the board's policies.
Arnold Oronsky, Independent Chairman of the Board
Francis Cano, Independent Director
Daniel Kisner, Independent Director
Dennis Carson, Independent Director
Robert Janssen, Chief Medical Officer, Vice President - Clinical Development and Regulatory Affairs
Eddie Gray, CEO and Director
Peggy Phillips, Independent Director
Nicole Arndt, Sr Relations
Laura Brege, Director
David Johnson, Chief Accounting Officer, Vice President
Andrew Hack, Director
John Slebir, Senior Counsel
Jeff Coon, CHRO Administration
Meg Smith, VP Operations
Todd Lopeman, Senior Operations
Stanley Plotkin, Independent Director
Dan Kisner, Independent Director
Riccardo Manetti, Business President
Eric Frings, Site VP
Natale Ricciardi, Director
David Novack, Sr. VP of Operations and Quality
Donn Casale, Chief Officer
Kelly MacDonald, Senior CFO
Paul Cox, VP Communications
Dong Yu, Senior Research
Ryan Spencer, Interim Co-President Co-Principal Executive Officer
Robert Coffman, Chief Scientific Officer and Sr. VP
Justin Burgess, Principal Controller
Michael Ostrach, Principal Financial Officer, Vice President General Counsel, Chief Business Officer

Dynavax Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Dynavax Technologies a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Dynavax Technologies Investors Sentiment

The influence of Dynavax Technologies' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Dynavax. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Dynavax Technologies' public news can be used to forecast risks associated with an investment in Dynavax. The trend in average sentiment can be used to explain how an investor holding Dynavax can time the market purely based on public headlines and social activities around Dynavax Technologies. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Dynavax Technologies' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Dynavax Technologies' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Dynavax Technologies' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Dynavax Technologies.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Dynavax Technologies in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Dynavax Technologies' short interest history, or implied volatility extrapolated from Dynavax Technologies options trading.

Pair Trading with Dynavax Technologies

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Dynavax Technologies position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dynavax Technologies will appreciate offsetting losses from the drop in the long position's value.

Moving together with Dynavax Stock

  0.7JNJ Johnson Johnson Financial Report 18th of July 2024 PairCorr

Moving against Dynavax Stock

  0.58NUVB Nuvation Bio Financial Report 2nd of May 2024 PairCorr
  0.52JSPRW Jasper TherapeuticsPairCorr
  0.45IOVA Iovance Biotherapeutics Financial Report 14th of May 2024 PairCorr
The ability to find closely correlated positions to Dynavax Technologies could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Dynavax Technologies when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Dynavax Technologies - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Dynavax Technologies to buy it.
The correlation of Dynavax Technologies is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Dynavax Technologies moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Dynavax Technologies moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Dynavax Technologies can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Dynavax Technologies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Dynavax Technologies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Dynavax Technologies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Dynavax Technologies Stock:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Dynavax Technologies. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation.
For more information on how to buy Dynavax Stock please use our How to Invest in Dynavax Technologies guide.
Note that the Dynavax Technologies information on this page should be used as a complementary analysis to other Dynavax Technologies' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.

Complementary Tools for Dynavax Stock analysis

When running Dynavax Technologies' price analysis, check to measure Dynavax Technologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dynavax Technologies is operating at the current time. Most of Dynavax Technologies' value examination focuses on studying past and present price action to predict the probability of Dynavax Technologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dynavax Technologies' price. Additionally, you may evaluate how the addition of Dynavax Technologies to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Positions Ratings
Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Analyst Advice
Analyst recommendations and target price estimates broken down by several categories
Fundamental Analysis
View fundamental data based on most recent published financial statements
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
CEOs Directory
Screen CEOs from public companies around the world
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Latest Portfolios
Quick portfolio dashboard that showcases your latest portfolios
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Is Dynavax Technologies' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Dynavax Technologies. If investors know Dynavax will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Dynavax Technologies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Earnings Share
(0.05)
Revenue Per Share
1.804
Quarterly Revenue Growth
(0.70)
Return On Assets
(0.02)
The market value of Dynavax Technologies is measured differently than its book value, which is the value of Dynavax that is recorded on the company's balance sheet. Investors also form their own opinion of Dynavax Technologies' value that differs from its market value or its book value, called intrinsic value, which is Dynavax Technologies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Dynavax Technologies' market value can be influenced by many factors that don't directly affect Dynavax Technologies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Dynavax Technologies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Dynavax Technologies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Dynavax Technologies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.